A Pragmatic Approach to the Diagnosis of Nodal Micrometastases in Early Stage Non-small Cell Lung Cancer

被引:12
作者
Herpel, Esther [2 ]
Muley, Thomas [3 ]
Schneider, Thomas [1 ]
Palm, Elisa [2 ]
de Hol, Doerthe Kieslich [2 ]
Warth, Arne [2 ]
Meister, Michael [3 ]
Storz, Konstantina [1 ]
Schnabel, Philipp A. [2 ]
Schirmacher, Peter [2 ]
Dienemann, Hendrik [1 ]
Hoffmann, Hans [1 ]
机构
[1] Heidelberg Univ, Thoraxklin, Dept Thorac Surg, Heidelberg, Germany
[2] Heidelberg Univ, Inst Pathol, Dept Gen Pathol, D-6900 Heidelberg, Germany
[3] Thoraxklin Heidelberg, Translat Res Unit, Heidelberg, Germany
关键词
Micrometastases; Lymph node; Lung cancer; Immunohistochemistry; Prognostic impact; ISOLATED TUMOR-CELLS; LYMPH-NODES; PROGNOSTIC-SIGNIFICANCE; MESSENGER-RNA; CARCINOMA; CLASSIFICATION; IMPACT; METASTASIS; RECURRENCE; RESECTION;
D O I
10.1097/JTO.0b013e3181e15cfd
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: This study was designed to develop a both sensitive and efficient algorithm for detection of lymph node micrometastases and to determine its prognostic impact in patients with early stage non-small cell lung cancer (NSCLC). Methods: One hundred seventy patients with NSCLC p stage I and II were included in this study, of which n = 5299 lymph nodes were obtained and submitted to histopathologic analysis. From each patient, a median number of 31 lymph nodes was received (N-1 position: median n = 16; N-2 position: median n = 15). Immunohistochemistry was performed to detect micrometastases unobvious by conventional microscopy using antibodies against cytokeratins (CK) (pan-CK: KL-1, CK 5/6, CK 7) and the epithelial marker Ber-EP4. Results: In 82 patients (48.2%), micrometastases were revealed in immunohistochemistry staining. KL-1 detected micrometastases in 201 (99.5%) of 202 positive lymph nodes. Subsequently, this resulted in an upstaging in 39 patients (20.5%). Detection of micrometastases in otherwise tumor-free N2-lymph nodes had a significant prognostic impact (mean disease-free survival 21.4 versus 45.3 months, p = 0.022), affecting 4.7% of patients. Survival differences between patients who were upstaged into stage II (N0 > N1) and those remaining in stage I were not statistically significant (p = 0.537). Conclusion: Extended workup of N2-lymph nodes using one broad-spectrum keratin marker in otherwise N2-negative lymph nodes may represent a both efficient and sensitive approach to the identification of micrometastases in dissected lymph nodes of patients with early stage NSCLC.
引用
收藏
页码:1206 / 1212
页数:7
相关论文
共 37 条
  • [1] AJCC, 2009, AJCC CANC STAG MAN
  • [2] Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers
    Au, NHC
    Cheang, M
    Huntsman, DG
    Yorida, E
    Coldman, A
    Elliott, WM
    Bebb, G
    Flint, J
    English, J
    Gilks, CB
    Grimes, HL
    [J]. JOURNAL OF PATHOLOGY, 2004, 204 (01) : 101 - 109
  • [3] Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas
    Camilo, R
    Capelozzi, VL
    Siqueira, SAC
    Del Carlo Bernardi, F
    [J]. HUMAN PATHOLOGY, 2006, 37 (05) : 542 - 546
  • [4] FREQUENCY AND DISTRIBUTION OF OCCULT MICROMETASTASES IN LYMPH-NODES OF PATIENTS WITH NON-SMALL-CELL LUNG-CARCINOMA
    CHEN, ZL
    PEREZ, S
    HOLMES, EC
    WANG, HJ
    COULSON, WF
    WEN, DR
    COCHRAN, AJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (06): : 493 - 498
  • [5] Coello Michael C, 2004, Clin Lung Cancer, V5, P214
  • [6] Discriminating between micrometastases and isolated tumor cells in a regional and institutional setting
    Cserni, G.
    Sapino, A.
    Decker, T.
    [J]. BREAST, 2006, 15 (03) : 347 - 354
  • [7] Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer - Impact on recurrence and survival
    Gu, CD
    Osaki, T
    Oyama, T
    Inoue, M
    Kodate, M
    Dobashi, K
    Oka, T
    Yasumoto, K
    [J]. ANNALS OF SURGERY, 2002, 235 (01) : 133 - 139
  • [8] Hashimoto T, 2000, CANCER RES, V60, P6472
  • [9] Hermanek P, 1999, ANTICANCER RES, V19, P2771
  • [10] Hermanek P, 1999, CANCER-AM CANCER SOC, V86, P2668, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2668::AID-CNCR11>3.0.CO